AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01960153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
Study NCT01960153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
Study NCT02725866 — intervention group
Intervention type: DRUG
Intervention: Paritaprevir/ritonavir/ombitasvir
Description: Co-formulated tablet
Study NCT02725866 — intervention group
Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet
Study NCT02725866 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study NCT03076294 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
Study NCT03076294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
Study NCT03076294 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual therapy (MT)
Description: This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
Study NCT03076294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Description: This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
Study NCT03455660 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02723084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Co-formulated tablet
Study NCT02723084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir (SOF)
Description: Tablet
Study NCT02723084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin (RBV)
Description: Capsule
Study NCT04377360 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha-emitter Radiation Therapy
Description: Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
Study NCT04930679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andiabet
Description: Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
Study NCT00266799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (SCH 200746)
Description: pegylated liposomal doxorubicin (50 mg/m\^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
Study NCT00266799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine (1250 mg/m\^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
Study NCT01116895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 22811
Description: Oral solution
Study NCT01116895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03718728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind&Life
Description: Acceptance and mindfulness-based group intervention program.
Study NCT02593318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA) 1g
Description: Pills to be taken orally in 500mg dose two times per day
Study NCT02593318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA) 2g
Description: Pills to be taken orally in 1000mg dose two times per day.
Study NCT05281055 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular thrombectomy
Description: Timely thrombectomy for acute ischemic stroke patients with large vessel occlusion by either stent retriever, thrombosuction, others, or combination methods.
Study NCT01352312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
Study NCT01352312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
Study NCT01352312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
Study NCT04228094 — intervention group
Intervention type: OTHER
Intervention: TDApp1: an eHealth intervention
Description: TDApp1 is a tool that uses GRADE heuristics to formulate participatory, individualized and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder
Study NCT01918566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
Study NCT01918566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25g Fructose in 300ml tap water
Study NCT01918566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
Study NCT01918566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 300ml tap water with 450ppm lactisole
Study NCT02729909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone capsules
Study NCT02729909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lubiprostone placebo-matching capsules
Study NCT02699073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity.
Study NCT00006760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
Study NCT01605721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE PRIMETM everolimus-eluting coronary stent
Description: Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM
Study NCT02085330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: 100%, 2 ATA, 90 minutes
Study NCT06099834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients selection
Description: Patient selection were selected according to selected criteria.
Study NCT06099834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implnat placement
Description: dental implants were applied as recommended by the manufacturer.
Study NCT06099834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recall visits
Description: Following the operations, the stability of the dental implants was measured at the 1st (T1), 4th (T4), and 12th (T12) weeks using Periotest (Periotest M, Modautal/Germany) and Osstell (Osstell AB-W\&H, Sweden) devices.
Study NCT00698334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH, Rifampicin, Ethambutol and Pyrazinamide
Description: Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
Study NCT00698334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INH, Rifampicin, Ethambutol and Pyrazinamide
Description: Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg \[600 mg if more than 59 kg\], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
Study NCT03012867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diben, Fresenius Kabi
Description: Patients receive Diben continously for 7 days
Study NCT03012867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin original fibre, Fresenius Kabi
Description: Patients receive Fresubin original fibre continously for 7 days
Study NCT01892891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBY-036
Description: Cathepsin S inhibitor
Study NCT00991406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: Surface stimulation to contract the muscles in the lower extremity
Study NCT03450733 — intervention group
Intervention type: DEVICE
Intervention: Wright Medical Technology Metal-on-Metal Total Hip System
Description: Subjects in Group 1 previously implanted prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 5 years, 6 years) using contiguous visit windows (number of years + 6 months). Subject data will be grouped in order to create cross-sectional epochs of ≤ 8 years and > 8 years.
Study NCT03824587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Description: Active Drug
Study NCT03824587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Drug
Study NCT03824587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Binder Agents
Description: standard of care phosphate binder use at study entry was maintained throughout the entire study
Study NCT03824587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Binder Agents
Description: standard of care phosphate binder use at study entry was maintained throughout the entire study
Study NCT02501525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS with ureteral access sheath
Description: Ureteral access sheath will be used during RIRS.
Study NCT00730782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfAMA-1-FVO[25-545]
Description: Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
Study NCT01028508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium and Venlafaxine
Description: Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
Study NCT01028508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECT
Description: Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
Study NCT03303404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory (24-hour) Blood Pressure
Description: Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
Study NCT00308503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration
Study NCT00308503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT03462550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Description: LMA insertion
Study NCT03462550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: LMA insertion
Study NCT02522286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ask 3 Questions
Description: Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare.
Study NCT02522286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Communication
Description: Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow.
Study NCT01700855 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non-electroacupuncture
Description: The same procedure as electroacupuncture except stimulation
Study NCT03718728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Personalized diet and physical exercise recommendations.
Study NCT03718728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Personalized diet and physical exercise recommendations.
Study NCT02054624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months.
Study NCT02054624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight.
Study NCT02054624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual
Description: The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months.
Study NCT02054624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: All Groups
Description: All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
Study NCT01433328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine
Study NCT01433328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01172795 — intervention group
Intervention type: BEHAVIORAL
Intervention: Relaxation session
Description: 30 minutes relaxation session (audiotape)
Study NCT01172795 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive test battery
Description: the psychomotor vigilance task, span task and the stroop task on computer
Study NCT00006760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: V over 24 hours on days 1-4
Study NCT00006760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: IV over 6-10 minutes on days 1 and 5.
Study NCT02501525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS without ureteral access sheath
Description: Ureteral access sheath will not be used during RIRS.
Study NCT02919514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on hard surface.
Description: Physical training on hard surface.
Study NCT02919514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training on sand surface.
Description: Physical training on sand surface.
Study NCT01070511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil will be administered orally on two consecutive days. The first dose-10 mg- will be administered the afternoon before the study. The second dose -20 mg-will be administered the morning of the study.
Study NCT01070511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
Study NCT02919514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on sand surface.
Description: Physical training on sand surface.
Study NCT02919514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training on soft surface.
Description: Physical training on soft surface.
Study NCT02919514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training on soft surface.
Description: Physical training on soft surface.
Study NCT04424693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tdap Vaccine Administration
Description: Tdap vaccinations are routinely given during pregnancy between weeks 27 and 36 per guidelines of American College Obstetrics and Gynecology (ACOG) -- but this study uniquely is trying to establish that the earlier Tdap vaccinations reduce preeclampsia by more than 50%
Study NCT01446744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
Study NCT03335280 — intervention group
Intervention type: DRUG
Intervention: 68Ga-citrate PET/MR
Description: Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.